Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 02/07/2009 HCMV has been detected in a renal artery organ model. The electron microscope image clearly shows the spiky spherical pathogen.

    A virus that hides while it waits for an opportunity to replicate

    Thomas Mertens, Medical Director of the Institute of Virology in Ulm, has a strong scientific and clinical interest in the human cytomegalovirus (HCMV), a big virus with a big impact which, despite its size, is overshadowed by known viruses such as the HI virus that is the object of research for Mertens’ colleagues. HCMV research is a challenging area where quick successes are rare.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-virus-that-hides-while-it-waits-for-an-opportunity-to-replicate
  • Press release - 30/06/2009 08933_de.jpg

    Gentle rather than radical: ways to improve the treatment of autoimmune diseases

    Autoimmune diseases are usually treated with drugs that block the entire immune system rendering the body very susceptible to all kinds of infections. A team of Constance researchers under the leadership of Prof. Marcus Groettrup has developed a treatment method that only targets part of the immune system and is therefore far better tolerated by patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gentle-rather-than-radical-ways-to-improve-the-treatment-of-autoimmune-diseases
  • Press release - 24/06/2009 08916_de.jpg

    Artificial liver for drug testing

    The liver is one of the most important metabolic organs in humans. Johanna Schanz and Heike Mertsching, two scientists from Fraunhofer have developed a model of the liver that is both viable outside the body and suitable for testing drugs. For their work, the two researchers have been awarded the Technology for People award, along with a cheque for 10,000 euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-liver-for-drug-testing
  • Press release - 28/05/2009 07777_de.jpg

    CureVac Begins Clinical Study with mRNA Vaccine

    CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
  • Press release - 26/03/2009 08265_de.jpg

    Sygnis Pharma AG increases capital

    SYGNIS Pharma AG reported its financial results for the first nine months of the fiscal year 20082009. The company improved its cash position significantly as a result of a successful capital increase. Following the capital increase the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to approximately 44.90 of the total share capital. The preparations for the phase II efficacy trial of its lead candidate AX200 in acute ischemic stroke…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-pharma-ag-increases-capital
  • Article - 17/02/2009 08087_de.jpg

    Tissue engineering companies and EU obstacles

    With the new regulation on advanced therapy medicinal products the European Union has tried to establish legal certainty with regard to gene therapy somatic cell therapy and tissue engineering products. However Dr. Heinz W. Joseph of TETEC AG is sure that the new guidelines will lead to problems for small and medium-sized companies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tissue-engineering-companies-and-eu-obstacles
  • Article - 02/02/2009

    CureVac enters premier biotech league with new cancer vaccine

    At present active immunotherapy seems to produce the best results in the treatment of cancer. The Tübingen-based biotech company CureVac is now hoping to achieve a breakthrough in cancer therapy with a worldwide unique vaccine. The first clinical trials have recently commenced.

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-enters-premier-biotech-league-with-new-cancer-vaccine
  • Article - 14/01/2009 Prof. Sabine Kloth, expert for materials of animal origin at TÜV SÜD Product Service GmbH

    Strict requirements for the market approval of tissue engineering products

    New regulations for the marketing approval of advanced therapy medicinal products have applied in the EU since December 2008. Prof. Sabine Kloth from TÜV SÜD Product Service GmbH is an expert in materials of animal origin and has been closely following the formulation of the ATMP Regulation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/strict-requirements-for-the-market-approval-of-tissue-engineering-products
  • Press release - 14/01/2009

    IND Approval for CureVac

    CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ind-approval-for-curevac
  • Article - 11/12/2008

    New drug that targets metastasing breast cancer in clinical phase III trial

    Protein kinases are a major focus of modern cancer research. Since it has become known that these enzymes play a role in the development of tumours, researchers around the world are concentrating on finding drugs to inhibit overactive protein kinases and prevent cancer cells from growing. One of these active substances is currently being tested at the Tumour Biology Centre in Freiburg as part of a worldwide phase III clinical trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-that-targets-metastasing-breast-cancer-in-clinical-phase-iii-trial
  • Press release - 10/12/2008

    CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer

    The German regulatory authority has approved the Clinical Trial Application CTA to begin a Phase I clinical study with RNActive - derived mRNA vaccine CV9103. It will be tested in patients with hormone-refractory metastatic prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-to-start-first-mrna-vaccine-clinical-trial-in-prostate-cancer
  • Article - 03/12/2008

    Esslingen scientists to recalculate human age

    The actual age of a person not only depends on the date he or she was born. Biological age, which is far more important in determining lifespan, can so far only be estimated rather than precisely calculated. The European MARK-AGE research project is working on finding a solution to this problem. Esslingen plays a major role in this project for two reasons: the structure of the city and the company BioTeSys.

    https://www.gesundheitsindustrie-bw.de/en/article/news/esslingen-scientists-to-recalculate-human-age
  • Article - 19/11/2008

    cr.appliance- integrated concepts in drug development

    Karen Grave-Hermann and Dr. Robert Hermann founded cr.applications in 2003. The two specialists who have wide-ranging experience in drug development talked to Michael Statnik about current trends in their field and about the development of the German biotech sector.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cr-appliance-integrated-concepts-in-drug-development
  • Press release - 17/10/2008

    Three anti-diabetes compounds in advanced clinical testing

    Boehringer Ingelheim has three oral compounds for the treatment of diabetes type II in phase II and III of clinical development. The most advanced compound a DPP-4 inhibitor is in the final clinical phase.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-anti-diabetes-compounds-in-advanced-clinical-testing
  • Press release - 13/10/2008

    Phenex AG closes €8.2 million financing round

    A consortium is providing funding for the development of Phenex drug candidates for type 2 diabetes and metabolic syndrome. Phenex will take its metabolic syndrome drug candidates into Phase I clinical testing by early 2010 at the latest.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/phenex-ag-closes-8-2-million-financing-round
  • Article - 08/09/2008

    Research increases hope

    Duchenne muscular dystrophy DMD is a severe disease affecting boys characterised by rapid progression of muscle degeneration so that boys as young as 10 to 12 years of age have to use a wheelchair and leading to death in young men. In Germany about 2500 children and young adults suffer from DMD.

    https://www.gesundheitsindustrie-bw.de/en/article/news/research-increases-hope
  • Press release - 25/08/2008

    Cross-border fight against cancer

    The Lake Constance region offers a broad range of cancer therapies and is home to several institutes and companies that are dealing with cancer research. The BioLAGO biotechnology network offers them a joint platform for co-operation and exchange of information.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cross-border-fight-against-cancer
  • Article - 18/08/2008

    Vitamin D reduces mortality risk

    The medical importance of vitamin D calciferol is most likely even higher than suggested by recently published studies. A study which also involves the endocrinologist Bernhard Böhm from Ulm has attracted enormous attention as it suggests that vitamin D deficiency increases mortality.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vitamin-d-reduces-mortality-risk
  • Article - 01/08/2008

    Nycomed - collaboration with Immunomedics

    Under the agreement Nycomed will receive the exclusive worldwide rights to develop manufacture and commercialise the subcutaneous formulation of veltuzumab for the treatment of all non-cancer indications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-collaboration-with-immunomedics
  • Article - 29/07/2008

    Frank Kirchhoff advances AIDS research by posing the right questions

    Frank Kirchhoff an AIDS researcher from Ulm has learnt to pose important questions and find the right answers during his post-graduate studies. This recipe has brought him and his research group international recognition and makes him one of the best AIDS researchers worldwide. Important publications within a very short time and numerous awards are clear evidence of his outstanding achievements. In addition he has just started a clinical trial…

    https://www.gesundheitsindustrie-bw.de/en/article/news/frank-kirchhoff-advances-aids-research-by-posing-the-right-questions
  • Article - 28/07/2008

    25 amino acids against avian influenza

    About a year ago Prof. Dr. Martin Schwemmle and his team at the University Hospital of Freiburg discovered a new starting point in the fight against the H5N1-virus. In the meantime the scientists are working together with the company Pike Pharma to develop a compound.

    https://www.gesundheitsindustrie-bw.de/en/article/news/25-amino-acids-against-avian-influenza
  • Article - 07/07/2008

    5th Clinical Trials Call

    DFG and BMBF will provide 15 million euros per year each starting in 2009.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/5th-clinical-trials-call
  • Article - 05/06/2008

    CureVac: partnership with University of Florida,

    CureVac GmbH has entered into a partnership with the Department of Urology University of Florida Gainesville U.S. to jointly advance its lead candidate CV9103 into the clinical development. The alliance covers preclinical studies and a US phase III trial.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-partnership-with-university-of-florida
  • Article - 28/04/2008 From left to right: Dr. Dr. Thomas Luft, patient Bruno Grimm, Professor Dr. Peter Dreger, Head of the Section of Allogeneic Stem Cell Transplantation.

    A milestone in the treatment of leukaemia

    Blood cancer experts in the team of Professor Peter Dreger Head of the Section of Allogeneic Stem Cell Transplantation at the University Hospital of Heidelberg have achieved a major success in the treatment of leukaemia. For the 500th time the physicians from the Department of Haematology Oncology and Rheumatology transferred blood stem cells from a healthy donor to a patient suffering from leukaemia or lymphoma.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/a-milestone-in-the-treatment-of-leukaemia
  • Press release - 28/04/2008

    Rentschler: experts in contract manufacturing

    The company Rentschler from Laupheim in the south of Germany is nowadays one of the biggest biopharmaceutical contract manufacturers in Europe. This has not always been the case. A look at the companys history shows why the company which is nowadays run by the third family generation has become what it is today.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-experts-in-contract-manufacturing

Page 9 / 10

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search